- Home
- JAZZ vs AGI Comparison
JAZZ vs AGI Comparison
Compare JAZZ & AGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | AGI |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | Ireland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 15.8B |
| IPO Year | 2007 | 2002 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | AGI |
|---|---|---|
| Price | $239.79 | $35.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 2 |
| Target Price | ★ $217.57 | $51.50 |
| AVG Volume (30 Days) | 877.4K | ★ 3.2M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.17 | N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.22 | $59.50 |
| Revenue Next Year | $7.68 | $14.28 |
| P/E Ratio | ★ $34.01 | $34.21 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $125.79 | $27.05 |
| 52 Week High | $266.38 | $55.41 |
Technical Indicators
Market Signals| Indicator | JAZZ | AGI |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 53.17 |
| Support Level | $236.70 | $35.50 |
| Resistance Level | $242.66 | $38.97 |
| Average True Range (ATR) | 5.77 | 1.12 |
| MACD | -0.36 | -0.33 |
| Stochastic Oscillator | 32.04 | 51.05 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About AGI Alamos Gold Inc.
Alamos Gold Inc acquires, explores, and produces gold and other precious metals, and operates in two principal geographic areas: Canada and Mexico. The company has three operating segments being Young-Davidson, Island Gold District's operation operates in Canada, and the Mulatos mine operates in Sonora, Mexico. The company generates maximum revenue from the Island Gold District mines.